Solmaz Sahebjam

Nov 16, 2023 | nature.com | Nancy Lin |Solmaz Sahebjam |Nuhad K. Ibrahim

AbstractThe PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy. Primary analysis confirmed CNS objective response rate (ORR) was 11% (95% confidence interval [CI]: 3–25); clinical benefit rate (CBR) was 68% (4 months) and 51% (6 months).

Jul 24, 2023 | nature.com | Ian F. Parney |Solmaz Sahebjam |Nader Sanai |Michael Platten |Michael Lim |Timothy F. Cloughesy | +11 more

A breakthrough in drug discovery for glioblastoma requires serial collection of tissue from the central nervous system via window of opportunity trials Therapeutic drug development in glioblastoma has remained static despite numerous clinical trials, advances in tumor biology, and substantial public interest. Since 2005, more than 1,250 interventional glioblastoma trials have been registered on ClinicalTrials.gov.